Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (271-280 of 504) with videos related to

Pageof 51
Sort By:
Cancer Research|July 23, 2003
Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancersJiuhong Yuan, Robert Z Luo, Satoshi Fujii, et al.
British Journal of Haematology|November 22, 2007
ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanismsJunya Kuroda, Shinya Kimura, Michael Andreeff, et al.
Oncotarget|December 20, 2017
Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activitiesXiao Huang, Mengru Cao, Shuhong Wu, et al.
British Journal of Haematology|October 3, 2002
Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndromeNaoto T Ueno, Athanasios Anagnostopoulos, Gabriela Rondón, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemiaFrancis Giles, Deborah Thomas, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemiaEttore Biagi, Raphael Rousseau, Eric Yvon, et al.
Blood Advances|November 22, 2019
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AMLNeil Beeharry, Sean Landrette, Sophia Gayle, et al.
Haematologica|October 13, 2022
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagyWeiguo Zhang, Guopan Yu, Hongying Zhang, et al.
Blood Neoplasia|August 4, 2025
PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AMLKotoko Yamatani, Tatsuro Watanabe, Kaori Saito, et al.
Cell Reports. Medicine|May 11, 2024
Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult miceRasoul Pourebrahim, Rafael Heinz Montoya, Hiroki Akiyama, et al.
Pageof 51

Showing results (271-280 of 504) with videos related to

Sort By:
Pageof 51
Cancer Research|July 23, 2003
Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancersJiuhong Yuan, Robert Z Luo, Satoshi Fujii, et al.
British Journal of Haematology|November 22, 2007
ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanismsJunya Kuroda, Shinya Kimura, Michael Andreeff, et al.
Oncotarget|December 20, 2017
Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activitiesXiao Huang, Mengru Cao, Shuhong Wu, et al.
British Journal of Haematology|October 3, 2002
Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndromeNaoto T Ueno, Athanasios Anagnostopoulos, Gabriela Rondón, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemiaFrancis Giles, Deborah Thomas, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemiaEttore Biagi, Raphael Rousseau, Eric Yvon, et al.
Blood Advances|November 22, 2019
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AMLNeil Beeharry, Sean Landrette, Sophia Gayle, et al.
Haematologica|October 13, 2022
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagyWeiguo Zhang, Guopan Yu, Hongying Zhang, et al.
Blood Neoplasia|August 4, 2025
PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AMLKotoko Yamatani, Tatsuro Watanabe, Kaori Saito, et al.
Cell Reports. Medicine|May 11, 2024
Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult miceRasoul Pourebrahim, Rafael Heinz Montoya, Hiroki Akiyama, et al.
Pageof 51